|
1
|
Hwang TL, Jan YY, Jeng LB, Chen MF, Hung
CF and Chiu CT: The different manifestation and outcome between
pancreatitis and pancreatic malignancy with left-sided portal
hypertension. Int Surg. 84:209–212. 1999.PubMed/NCBI
|
|
2
|
Koklu S, Yuksel O, Arhan M, Coban S, Başar
O, Yolcu OF, Uçar E, Ibiş M, Ertugrul I and Sahin B: Report of 24
left-sided portal hypertension cases: A single-center prospective
cohort study. Dig Dis Sci. 50:976–982. 2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sakorafas GH, Sarr MG, Farley DR and
Farnell MB: The significance of sinistral portal hypertension
complicating chronic pancreatitis. Am J Surg. 179:129–133.
2000.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Turrill FL and Mikkelsen WP: ‘Sinistral’
(left-sided) extrahepatic portal hypertension. Arch Surg.
99:365–368. 1969.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hubert C, Sempoux C, Humblet Y, van den
Eynde M, Zech F, Leclercq I and Gigot JF: Sinusoidal obstruction
syndrome (SOS) related to chemotherapy for colorectal liver
metastases: Factors predictive of severe SOS lesions and protective
effect of bevacizumab. HPB (Oxford). 15:858–864. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Overman MJ, Maru DM, Charnsangavej C,
Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA
and Kopetz S: Oxaliplatin-mediated increase in spleen size as a
biomarker for the development of hepatic sinusoidal injury. J Clin
Oncol. 28:2549–2555. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aarnink A, Richard C, Truntzer C, Vincent
J, Bengrine L, Vienot A, Borg C and Ghiringhelli F: Baseline
splenic volume as a surrogate marker of FOLFIRINOX efficacy in
advanced pancreatic carcinoma. Oncotarget. 9:25617–25629.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Common Terminology Criteria for Adverse
Events(CTCAE), version 5.0. US Department of Health and Human
Services, 2017. urihttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdfsimplehttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
Accessed November 27, 2017.
|
|
9
|
Kamarajah SK, Burns WR, Frankel TL, Cho CS
and Nathan H: Validation of the American joint commission on cancer
(AJCC) 8th edition staging system for patients with pancreatic
adenocarcinoma: A surveillance, epidemiology and end results (SEER)
analysis. Ann Surg Oncol. 24:2023–2030. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Harris A, Kamishima T, Hao HY, Kato F,
Omatsu T, Onodera Y, Terae S and Shirato H: Splenic volume
measurements on computed tomography utilizing automatically
contouring software and its relationship with age, gender, and
anthropometric parameters. Eur J Radiol. 75:e97–e101.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Global Burden of Disease Cancer
Collaboration. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd
Allah F, Abdel Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, et
al: Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2017:
A systematic analysis for the global burden of disease study. JAMA
Oncol. 5:1749–1768. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shirasu H, Todaka A, Omae K, Fujii H,
Mizuno N, Ozaka M, Ueno H, Kobayashi S, Uesugi K, Kobayashi N, et
al: Impact of UGT1A1 genetic polymorphism on toxicity in
unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Cancer Sci. 110:707–716. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Takahara N, Nakai Y, Isayama H, Sasaki T,
Satoh Y, Takai D, Hamada T, Uchino R, Mizuno S, Miyabayashi K, et
al: Uridine diphosphate glucuronosyl transferase 1 family
polypeptide A1 gene (UGT1A1) polymorphisms are associated with
toxicity and efficacy in irinotecan monotherapy for refractory
pancreatic cancer. Cancer Chemother Pharmacol. 71:85–92.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Prassopoulos P, Daskalogiannaki M,
Raissaki M, Hatjidakis A and Gourtsoyiannis N: Determination of
normal splenic volume on computed tomography in relation to age,
gender and body habitus. Eur Radiol. 7:246–248. 1997.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gabrilovich DI: Myeloid-derived suppressor
cells. Cancer Immunol Res. 5:3–8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kumar V, Patel S, Tcyganov E and
Gabrilovich DI: The nature of myeloid-derived suppressor cells in
the tumor microenvironment. Trends Immunol. 37:208–220.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Padoan A, Plebani M and Basso D:
Inflammation and pancreatic cancer: Focus on metabolism, cytokines,
and immunity. Int J Mol Sci. 20(676)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shalapour S and Karin M: Pas de Deux:
Control of anti-tumor immunity by cancer-associated inflammation.
Immunity. 51:15–26. 2019.PubMed/NCBI View Article : Google Scholar
|
